Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in the Netherlands

Acta Oncologica

Volumn 52, Issue 5, 2013, Pages 950-955

  Mol, Linda ^a   Koopman, Miriam ^b   Van Gils, Chantal W M ^c   Ottevanger, Petronella B ^d   Punt, Cornelis J A ^e  

^a Integraal Kankercentrum Oost   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ALKALINE PHOSPHATASE; CAPECITABINE; IRINOTECAN; LACTATE DEHYDROGENASE; OXALIPLATIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL PRACTICE; COLORECTAL CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NETHERLANDS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT OUTCOME; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; CANCER STAGING; CANCER SURVIVAL; EXTERNAL VALIDITY; LACTATE DEHYDROGENASE BLOOD LEVEL; METASTATIC COLORECTAL CANCER; MONOTHERAPY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; ORGANOPLATINUM COMPOUNDS; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 84877352669     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.777158     Document Type: Article

References (15)

1. Stiller C A . C entralised treatment, entry to trials and survival. Br J Cancer 1994; 70: 352-62 .
2. Peppercorn JM , W eeks JC, C ook EF, J offe S . C omparison of outcomes in cancer patients treated within and outside clinical trials: Conceptual framework and structured review . Lancet 2004; 363: 263-70 .
3. Braunholtz DA , E dwards SJ , L ilford RJ . A re randomized clinical trials good for us (in the short term)? Evidence for a trial effect. J Clin Epidemiol 2001; 54: 217-24 .
4. ECRI . P atients ' reasons for participation in clinical trials and effect of trial participation on patient outcomes . [cited 2010 Jun 26] Available from: https://www.ecri.org/Documents/Clinical-Trials-Patient-Guide- Evidence-Report.pdf;2002.
5. Vist G E , H agen K B, D evereaux P J , B ryant D , K ristoffersen DT , Oxman AD . Outcomes of patients who participate in randomised controlled trials compared to similar patients receiving similar interventions who do not participate . Cochrane Database Syst Rev 2007: MR000009 .
6. Koopman M , A ntonini N F , D ouma J , W als J , H onkoop AH , Erdkamp FL , et al . Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial . Lancet 2007; 370: 135-42 .
7. Koopman M , A ntonini N F , D ouma J , W als J , H onkoop AH , Erdkamp FL , et al . Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis . A Dutch Colorectal Cancer Group (DCCG) phase III study. Ann Oncol 2006; 17: 1523-8 .
8. Mekenkamp L J, K oopman M , T eerenstra S , v an Krieken J H, Mol L , Nagtegaal ID , et al . Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs . metachronous metastases. Br J Cancer 2010; 103: 159-64 .
9. Venderbosch S , de Wilt JH, Teerenstra S , Loosveld OJ, van Bochove A , Sinnige HA , et al . Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: Retrospective analysis of two randomized studies and a review of the literature . Ann Surg Oncol 2011; 18: 3252-60 .
10. Sateren WB, T rimble EL, A brams J, B rawley O, B reen N , Ford L , et al . How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials . JCO 2002; 20: 2109-17 .
11. Townsley CA , S elby R , S iu LL . S ystematic review of barriers to the recruitment of older patients with cancer onto clinical trials . JCO 2005; 23: 3112-24 .
12. Rothwell PM . E xternal validity of randomised controlled trials: To whom do the results of this trial apply? . Lancet 2005; 365: 82-93 .
13. Sorbye H, P feiffer P , C avalli-Bjorkman N , Q vortrup C, Holsen , MH , Wentzel-Larsen T , et al . Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients . Cancer 2009; 115: 4679-87 .
14. Power DG , L ichtman SM . C hemotherapy for the elderly patient with colorectal cancer . Cancer J 2010; 16: 241-52 .
15. Lara PN , Jr., Higdon R , L im N , K wan K, T anaka M , L au DH , et al . Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment . J Clin Oncol 2001; 19: 1728-33 .